Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Feb 15, 2024

BUY
$18.6 - $27.25 $32,977 - $48,314
1,773 New
1,773 $34,000
Q2 2022

Feb 14, 2024

BUY
$16.57 - $35.1 $29,378 - $62,232
1,773 New
1,773 $37,000
Q2 2022

Jul 26, 2022

BUY
$16.57 - $35.1 $29,378 - $62,232
1,773 New
1,773 $37,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $257M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.